✦ LIBER ✦

P-460 Results of a phase 2 trial of HGS-ETR1 (agonistic humanmonoclonal antibody to TRAIL receptor 1) in subjects with relapsedlrecurrent non-small cell lung cancer (NSCLC)

✍ Scribed by Bonomi, P.; Greco, F.; Crawford, J.; Kelly, K.; Oh, Y.; Klein, J.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

630 POSTER Results of a phase 2 study of

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 144 KB

Phase 2 study of mapatumumab, a fully hu

✍ Greco, F. Anthony; Bonomi, Philip; Crawford, Jeffrey; Kelly, Karen; Oh, Yun; Hal 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 214 KB

208 HGS-ETR1, a fully human monoclonal a

✍ S.J. Hotte; A.M. Oza; L.H. Le; M. MacLean; A. Iacobucci; A. Corey; N.L. Fox; H.W 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 151 KB

Phase II Trial of Mapatumumab, a Fully H

✍ von Pawel, Joachim; Harvey, Jimmie H.; Spigel, David R.; Dediu, Mircea; Reck, Ma 📂 Article 📅 2014 🏛 CIG Media Group, LP. 🌐 English ⚖ 569 KB

A phase 1 trial of the MEK1/2 inhibitor

✍ Koh, P. Keng; Califano, R.; Dean, E.; Kosmin, J.; Ataman, O.; Jackson, A.; Black 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 97 KB

9096 POSTER EGFR-targeting Chimeric Mono

✍ Kortsik, C.; Schmid-Bindert, G.; Pilz, L.R.; Cicenas, S.; Eschbach, C.; Kollmeie 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 44 KB